RxDoctor Payments Data

Pedro Santiago Rodriguez, MD

Cardiovascular Disease · Ponce, PRNPI 1083007264

Payments from drug & device makers

$6,033in general payments, 2019–2025

Across 220 payments — averaging $27.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Abbott$587
  • Johnson & Johnson$467
  • Medtronic$439
  • AstraZeneca$410
  • PBG Puerto Rico LLC$244
  • plus $1K from 10 others

What the payments were for

  • Food & beverage$5,89298%
  • Education$1412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific81$2,809
Abbott26$587
Johnson & Johnson25$467
Medtronic(2 entities)23$439
AstraZeneca18$410
PBG Puerto Rico LLC16$244
E.r. Squibb & Sons, L.L.C.9$239
Amgen3$167
Merck4$149
Novartis5$147
Pfizer Pharmaceuticals LLC1$121
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)5$107
Bayer1$97
Boehringer Ingelheim1$23
Cardinal Health P.r. 120 Inc1$15
Sanofi-aventis U.S. LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,033 in reported general payments places this provider in the 70th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$20,703
Medicare patients
33
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$51,970
FarxigaDapagliflozin Propanediol18$10,594
BrilintaTicagrelor21$9,679
EntrestoSacubitril/Valsartan12$8,291
XareltoRivaroxaban11$6,179
Metoprolol Succinate285$3,038
SynthroidLevothyroxine Sodium43$2,469
Atorvastatin Calcium245$2,131
Irbesartan66$1,575
Rosuvastatin Calcium128$1,402
Candesartan Cilexetil12$1,272
Amlodipine Besylate194$1,076
Lisinopril185$1,059
Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide42$850
Losartan Potassium127$794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$410$20,27339 claims
NovartisEntresto$147$8,29112 claims
Johnson & JohnsonXarelto$467$6,17911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →